Eusa Pharma completes $115m acquisition of Sylvant for iMCD treatment
Eusa Pharma has successfully acquired the global rights to Sylvant (siltuximab), a drug used in the treatment of idiopathic multicentric Castleman’s disease (iMCD), from Janssen ... Read More
Takeda’s $62bn acquisition of Shire: A game-changing move for global pharma
In a landmark deal, Takeda Pharmaceutical Company has successfully completed its previously announced acquisition of Shire, an Irish biotech leader specializing in rare diseases, for ... Read More
Innovent Biologics and Incyte announce $391.5m partnership for cancer drugs in China
Innovent Biologics, a leading Chinese biopharma company, has struck a landmark deal with Incyte, a prominent US pharmaceutical firm, to develop and commercialize three investigational ... Read More
Astellas Pharma acquires Potenza Therapeutics in $404.7m deal
Japanese pharmaceutical giant Astellas Pharma has announced the acquisition of US-based Potenza Therapeutics in a significant transaction valued at up to $404.7 million. This strategic ... Read More
Armas Pharmaceuticals launches first injectable in US with Vidaza generic
Armas Pharmaceuticals has entered the US injectable drug market with its launch of Azacitidine for Injection 100 MG, a generic version of Vidaza, targeting myelodysplastic ... Read More
Brooklyn Immuno Therapeutics acquires IRX Therapeutics’ assets for cytokine-based cancer therapy
Brooklyn Immuno Therapeutics, a New York-based clinical-stage biopharmaceutical company specializing in cytokine-based cancer therapies, has announced the acquisition of IRX Therapeutics' assets. The terms of ... Read More
Seattle Genetics’ Adcetris receives FDA approval for peripheral T-cell lymphoma
Seattle Genetics' Adcetris, in combination with CHP chemotherapy, gains FDA approval for treating certain types of peripheral T-cell lymphoma. Seattle Genetics has announced that the ... Read More
Fresenius Kabi launches generic Arsenic Trioxide Injection in US to enhance oncology treatment options
German health care company Fresenius Kabi has announced the US launch of its new generic drug, Arsenic Trioxide Injection. This product, a generic version of ... Read More
Pfizer’s Lorbrena receives FDA approval for advanced lung cancer treatment
Pfizer Inc., a leading US pharmaceutical company, has secured approval from the US Food and Drug Administration (FDA) for Lorbrena (lorlatinib), a groundbreaking treatment for ... Read More
Nordic Nanovector launches US Phase 2b trial for Betalutin in follicular lymphoma
Nordic Nanovector, a Norwegian biopharmaceutical company, has commenced the first clinical site in the United States for its PARADIGME trial. This pivotal trial is designed ... Read More